WAVE Life Sciences Ltd

1U5

Company Profile

  • Business description

    WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

  • Contact

    7 Straits View No. 12-00
    Marina One East Tower
    Singapore018936
    SGP

    T: +65 62363388

    E: [email protected]

    https://www.wavelifesciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    317

Stocks News & Analysis

stocks

Ask the analyst: Where does GYG stand following its US exit?

All roads lead back home for Guzman Y Gomez.
stocks

Chart of the Week: The long term headwinds facing copper shares

The key factors challenging the bull case for copper demand.
stocks

Australia’s oldest REIT undervalued

This REIT remains undervalued as trophy properties shine through.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,048.3074.600.83%
CAC 408,515.3740.510.48%
DAX 4025,812.86231.980.91%
Dow JONES (US)52,900.07594.831.14%
FTSE 10010,674.0621.190.20%
HKSE23,350.03295.001.28%
NASDAQ25,832.67207.36-0.80%
Nikkei 22569,744.071,010.921.47%
NZX 50 Index13,618.4236.230.27%
S&P 5007,483.240.010.00%
S&P/ASX 2008,844.4075.100.86%
SSE Composite Index4,043.6414.740.37%

Market Movers